Cargando…
Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
Although cardiac troponin is a highly specific biomarker for myocardial cell injury, it is important to recognize the pitfalls of this test in the diagnosis and management of immune checkpoint inhibitor (ICI) myocarditis. We describe the challenging case of an 81‐year‐old woman with persistently hig...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065849/ https://www.ncbi.nlm.nih.gov/pubmed/35352879 http://dx.doi.org/10.1002/ehf2.13915 |
_version_ | 1784699678989746176 |
---|---|
author | Ida, Mizuki Nakamori, Shiro Yamamoto, Shinya Watanabe, Seimi Imanaka‐Yoshida, Kyoko Ishida, Masaki Sakuma, Hajime Yamanaka, Keiichi Dohi, Kaoru |
author_facet | Ida, Mizuki Nakamori, Shiro Yamamoto, Shinya Watanabe, Seimi Imanaka‐Yoshida, Kyoko Ishida, Masaki Sakuma, Hajime Yamanaka, Keiichi Dohi, Kaoru |
author_sort | Ida, Mizuki |
collection | PubMed |
description | Although cardiac troponin is a highly specific biomarker for myocardial cell injury, it is important to recognize the pitfalls of this test in the diagnosis and management of immune checkpoint inhibitor (ICI) myocarditis. We describe the challenging case of an 81‐year‐old woman with persistently high troponin after undergoing immunotherapy with ipilimumab and nivolumab, and histological evidence of amyloid deposition in the myocardium. The patient received immunosuppressive treatments based on the magnitude of troponin changes because myocarditis was clinically suspected. However, histological examination revealed the deposition of transthyretin amyloid fibrils with only minimal T‐lymphocyte infiltration and no myocyte necrosis, suggesting transthyretin cardiac amyloidosis rather than ICI myocarditis. This case highlights the importance of assessing other causes of persistently high troponin, and the necessity of incorporating comprehensive histological and immunohistochemical examinations of the endomyocardial biopsy, especially when cardiovascular magnetic resonance imaging is inconclusive. |
format | Online Article Text |
id | pubmed-9065849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90658492022-05-04 Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits Ida, Mizuki Nakamori, Shiro Yamamoto, Shinya Watanabe, Seimi Imanaka‐Yoshida, Kyoko Ishida, Masaki Sakuma, Hajime Yamanaka, Keiichi Dohi, Kaoru ESC Heart Fail Case Reports Although cardiac troponin is a highly specific biomarker for myocardial cell injury, it is important to recognize the pitfalls of this test in the diagnosis and management of immune checkpoint inhibitor (ICI) myocarditis. We describe the challenging case of an 81‐year‐old woman with persistently high troponin after undergoing immunotherapy with ipilimumab and nivolumab, and histological evidence of amyloid deposition in the myocardium. The patient received immunosuppressive treatments based on the magnitude of troponin changes because myocarditis was clinically suspected. However, histological examination revealed the deposition of transthyretin amyloid fibrils with only minimal T‐lymphocyte infiltration and no myocyte necrosis, suggesting transthyretin cardiac amyloidosis rather than ICI myocarditis. This case highlights the importance of assessing other causes of persistently high troponin, and the necessity of incorporating comprehensive histological and immunohistochemical examinations of the endomyocardial biopsy, especially when cardiovascular magnetic resonance imaging is inconclusive. John Wiley and Sons Inc. 2022-03-30 /pmc/articles/PMC9065849/ /pubmed/35352879 http://dx.doi.org/10.1002/ehf2.13915 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Ida, Mizuki Nakamori, Shiro Yamamoto, Shinya Watanabe, Seimi Imanaka‐Yoshida, Kyoko Ishida, Masaki Sakuma, Hajime Yamanaka, Keiichi Dohi, Kaoru Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits |
title | Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits |
title_full | Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits |
title_fullStr | Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits |
title_full_unstemmed | Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits |
title_short | Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits |
title_sort | subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065849/ https://www.ncbi.nlm.nih.gov/pubmed/35352879 http://dx.doi.org/10.1002/ehf2.13915 |
work_keys_str_mv | AT idamizuki subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT nakamorishiro subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT yamamotoshinya subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT watanabeseimi subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT imanakayoshidakyoko subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT ishidamasaki subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT sakumahajime subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT yamanakakeiichi subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits AT dohikaoru subtlebutsmoulderingmyocardialinjuryafterimmunecheckpointinhibitortreatmentaccompaniedbyamyloiddeposits |